Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
May 31 AZN Ontario court approves AstraZeneca/Fusion acquisition plan
May 31 AZN The Most Profitable Biotechnology Company in the World
May 31 AZN Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
May 31 AZN AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
May 31 AZN Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
May 30 GYRE Gyre Therapeutics files to sell 1.08M shares of common stock for holders
May 30 GYRE Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 30 IXHL Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
May 30 GTLS Chart Industries (GTLS) Secures Compression Order in Portugal
May 30 AZN This Pharma Stock Is Poised to Keep Outperforming the S&P 500
May 30 AZN Goldman Sachs Says Buy European Pharma Stocks Touting Innovation
May 29 AZN Fusion shareholders give green light to AstraZeneca acquisition
May 29 AZN Amgen wins approval of first biosimilar of AstraZeneca's Soliris
May 29 AZN Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29 AZN AstraZeneca touts PCSK9 inhibitor in lowering LDL cholesterol when added to statin
May 29 AZN AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
May 29 AZN AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
May 29 AZN AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
May 28 AZN Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28 AZN Cellectis Reports Financial Results for First Quarter 2024
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags